Korea University Anam Hospital

anam.kumc.or.kr

Total trials

109

Active

31

Phase 3

7

Total enrollment

38,245

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Combination therapy2
Rivaroxaban 20 MG1
Rivaroxaban 15 MG1
Enavogliflozin1
Nicorandil1
High intensity statin monotherapy1
statins, ezetimibe1
Nelmastobart and Capecitabine1
Fruquintinib1
Niraparib1
Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin1
Dose escalation of moderate-intensity statin1
Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell1

Next readouts

  • 2025-12-01
  • 2025-12-31
  • 2026-04
  • 2026-06-30
  • 2026-06-30
  • 2026-07
  • 2027-02-01
  • 2027-03-01
  • 2028-01-25
  • 2029-08-31

Top conditions

  • Coronary Artery Disease7
  • Hypertension5
  • Colorectal Cancer4
  • Diabetes Mellitus4
  • Diabetes Mellitus, Type 24
  • Atrial Fibrillation3
  • Gastric Cancer3
  • Persistent Atrial Fibrillation3

Frequently asked questions about Korea University Anam Hospital

How many clinical trials does Korea University Anam Hospital have on ClinicalTrials.gov?
Korea University Anam Hospital is listed as the lead sponsor on 109 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
How many of Korea University Anam Hospital's trials are in Phase 3?
7 of Korea University Anam Hospital's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Korea University Anam Hospital focus on?
Korea University Anam Hospital's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Hypertension, Colorectal Cancer, Diabetes Mellitus, Diabetes Mellitus, Type 2.
When are Korea University Anam Hospital's next clinical trial readouts?
Korea University Anam Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer”, expected around 2025-12-01.